We are a blank check company backed by Cormorant Asset Management, L.P. , a leading life sciences-focused investment firm. We intend to focus our search for a target business in the healthcare sector or healthcare-related industries. (Incorporated in the Cayman Islands)

Our chairperson and CEO, Bihua Chen, founded Cormorant. She is also the managing member of Cormorant. Since its inception in 2013, Cormorant has focused on the healthcare industry and invests, throughout their growth cycle, in companies that discover and develop therapeutic drugs or medical technology. Cormorant is an active life-science investor with investments in over 100 privately held, life science-focused companies over this period. Of these investments, over 50 have completed initial public offerings. Notable successes include Prometheus Biosciences, Inc., Turning Point Therapeutics, Inc., and MyoKardia, Inc., each of which has been acquired for more than $4 billion. Other notable successes include BridgeBio Pharma Inc. and Apellis Pharmaceuticals Inc., each of which is a public company with a market capitalization greater than $1 billion.

An affiliate of Cormorant founded Helix Acquisition Corp. (“Helix I”), a special purpose acquisition company organized for purposes similar to those of our company, which raised $115 million in an initial public offering of ordinary shares in October 2020. On April 5, 2022, Helix I completed its initial business combination with MoonLake Immunotherapeutics AG (Nasdaq: MLTX) (“Moonlake”), a clinical-stage biopharmaceutical company focused on creating next-level therapies for inflammatory diseases. Ms. Chen was the chairperson and CEO of Helix I.

Note: Helix Acquisition Corp. II is offering 15.0 million shares – NOT units – at $10.00 each to raise $150.0 million. 

(Note: Helix Acquisition Corp. II upsized its SPAC IPO at pricing to 16.0 million shares – up from 15.0 million shares – and priced the deal at $10.00, as expected – to raise $160.0 million on Feb. 8, 2024. At pricing, Helix II became the second SPAC IPO priced in February. Background: Helix Acquisition Corp. II increased the size of its SPAC  IPO by 50 percent in an S-1/A filing dated Feb. 2, 2024, to 15.0 million shares –  up from 10.0 million shares initially – at $10.00 each – to raise $150.0 million.)